Cytokinetics, Incorporated
CYTK
$64.66
$1.151.81%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -127.86% | 16.73% | -7.57% | 6.56% | -12.02% |
| Total Depreciation and Amortization | 17.24% | -0.65% | -3.48% | -1.16% | 0.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 215.62% | 68.27% | -19.06% | -13.68% | 46.86% |
| Change in Net Operating Assets | 144.08% | -882.34% | -112.47% | 322.04% | 1.20% |
| Cash from Operations | 16.17% | 2.57% | -100.73% | 35.40% | -2.20% |
| Capital Expenditure | -125.67% | 26.82% | -339.07% | -84.02% | 63.39% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -208.06% | -48.91% | -0.48% | 352.87% | 93.17% |
| Cash from Investing | -234.22% | -50.09% | -4.43% | 346.07% | 93.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -14,918.87% | 6.45% | 1.03% | -0.69% | -0.56% |
| Issuance of Common Stock | 2.82% | -11.84% | 18.07% | 2.55% | -98.99% |
| Repurchase of Common Stock | -40.08% | -3,853.85% | 98.90% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -- | -- | -- | -100.00% |
| Cash from Financing | 320.80% | 1,551.94% | 99.41% | -30.39% | -99.58% |
| Foreign Exchange rate Adjustments | 106.74% | -152.59% | -192.47% | 331.75% | -887.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5,990.87% | 111.79% | -144.15% | 133.49% | -304.16% |